Wet Age-Related Macular Degeneration (AMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Wet Age-Related Macular Degeneration (AMD) Market Outlook

Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wet Age-Related Macular Degeneration (AMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Wet Age-Related Macular Degeneration (AMD) Overview

The most common cause of visual impairment among elderly patients in developed countries is wet age-related macular degeneration (ARMD), which is characterized by the growth of choroidal neovascularization (CNV) driven by vascular endothelial growth factor (VEGF). CNV can result in bleeding under the retina, detachment or atrophy of the retinal pigment epithelium (RPE), or fluid accumulation under the retina or RPE, leading to vision loss. Wet ARMD differs from dry ARMD by the presence of CNV, where new blood vessels from the choroid invade Bruch's membrane and proliferate either between the membrane and RPE or in the subretinal space. The multifactorial nature of wet ARMD includes numerous risk factors such as older age, elevated total serum cholesterol, micronutrient deficiency, smoking, family history, hypertension, cardiovascular disease, and visible light exposure. Genetic predisposition to ARMD is also apparent, with at least 34 genetic loci and 52 gene variants associated with the disease. Without treatment, most patients with wet ARMD will suffer irreversible vision loss.

• Approximately 10% of patients with ARMD develop neovascular disease. In the absence of anti-VEGF therapy, between 79% to 90% of those eyes will eventually become legally blind due to complications from neovascularization.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: